Clinical Trial Update: Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. [Phase 1, Phase 2]

View source ↗

Summary

The trial at MD Anderson Cancer Center is a Phase 1b/2 study of ipilimumab, nivolumab, and ciforadenant in first-line advanced renal cell carcinoma; the study s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Ciforadenant (ciforadenant)
• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Renal Cell Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING